Patient specific treatment planning for systemically administered radiopharmaceuticals using PET/CT and Monte Carlo simulation

Applied Radiation and Isotopes

Volumn 68, Issue 1, 2010, Pages 59-65

  Grudzinski, J J ^a   Yoriyaz, H ^b   DeLuca Jr , P M ^a   Weichert, J P ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b INSTITUTO DE PESQUISAS ENERGÉTICAS E NUCLEARES   (Brazil)

Author keywords

Monte Carlo; Patient specific dosimetry; PET CT; Radionuclide treatment planning

Indexed keywords

LIVER METASTASIS; MONTE CARLO; MONTE CARLO SIMULATION; PATIENT SPECIFIC; PATIENT SPECIFIC DOSIMETRY; PET IMAGING; PHYSICAL CHARACTERISTICS; RADIATION TRANSPORT; RADIATION TREATMENT PLANNING; RADIOLABELING; SOFTWARE INTERFACES; TARGETING MOLECULES; THERAPEUTIC PROCEDURES; TREATMENT PLANNING;

COMPUTER SIMULATION; DOSIMETERS; DOSIMETRY; LIVER; RADIOISOTOPES; RADIOTHERAPY; TUMORS;

MONTE CARLO METHODS;

ANTINEOPLASTIC AGENT; IODINE 124; IODINE 131; NM 404; UNCLASSIFIED DRUG;

ARTICLE; CANCER RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DOSIMETRY; LIVER METASTASIS; MONTE CARLO METHOD; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION ABSORPTION; RADIATION DOSE DISTRIBUTION; RADIOISOTOPE DISTRIBUTION; TREATMENT PLANNING;

HUMANS; IODINE RADIOISOTOPES; LIVER; LIVER NEOPLASMS; MONTE CARLO METHOD; PHANTOMS, IMAGING; PHOSPHORYLCHOLINE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; SOFTWARE;

EID: 70449716892     PISSN: 09698043     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.apradiso.2009.09.070     Document Type: Article

References (47)

1. Bai C., Kinahan P.E., Brasse D., Comtat C., Townsend D.W., Meltzer C.C., Villemagne V., Charron M., and Defrise M. An analytic study of the effects of attenuation on tumor detection in whole-body PET oncology imaging. Journal of Nuclear Medicine 44 (2003) 1855-1861
2. Barone R., Borson-Chazot F., Valkema R., Walrand S., Chauvin F., Gogou L., Kvols L.K., Krenning E.P., Jamar F., and Pauwels S. Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. Journal of Nuclear Medicine 46 Suppl. 1 (2005) 99S-106S
3. Bodey R.K., Evans P.M., and Flux G.D. Application of the linear-quadratic model to combined modality radiotherapy. International Journal of Radiation Oncology, Biology, Physics 59 (2004) 228-241
4. Brans B., Bodei L., Giammarile F., Linden O., Luster M., Oyen W.J., and Tennvall J. Clinical radionuclide therapy dosimetry: the quest for the Holy Gray. European Journal of Nuclear Medicine and Molecular Imaging 34 (2007) 772-786
5. Breitz H., Wendt R., Stabin M., Bouchet L., and Wessels B. Dosimetry of high dose skeletal targeted radiotherapy (STR) with 166Ho-DOTMP. Cancer Biotherapy & Radiopharmaceuticals 18 (2003) 225-230
6. Brenner D.J., Hlatky L.R., Hahnfeldt P.J., Huang Y., and Sachs R.K. The linear-quadratic model and most other common radiobiological models result in similar predictions of time-dose relationships. Radiation Research 150 (1998) 83-91
7. Brown S., Bailey D.L., Willowson K., and Baldock C. Investigation of the relationship between linear attenuation coefficients and CT Hounsfield units using radionuclides for SPECT. Applied Radiation and Isotopes 66 (2008) 1206-1212
8. Dale R., and Carabe-Fernandez A. The radiobiology of conventional radiotherapy and its application to radionuclide therapy. Cancer Biotherapy & Radiopharmaceuticals 20 (2005) 47-51
9. Dale R.G. The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy. British Journal of Radiology 58 (1985) 515-528
10. Dale R.G. Radiobiological assessment of permanent implants using tumour repopulation factors in the linear-quadratic model. British Journal of Radiology 62 (1989) 241-244
11. Dale R.G. Dose-rate effects in targeted radiotherapy. Physics in Medicine and Biology 41 (1996) 1871-1884
12. Delbeke D., Schoder H., Martin W.H., and Wahl R.L. Hybrid imaging (SPECT/CT and PET/CT): improving therapeutic decisions. Seminars in Nuclear Medicine 39 (2009) 308-340
13. Dewaraja Y.K., Wilderman S.J., Koral K.F., Kaminski M.S., and Avram A.M. Use of integrated SPECT/CT imaging for tumor dosimetry in I-131 radioimmunotherapy: a pilot patient study. Cancer Biotherapy & Radiopharmaceuticals 24 (2009) 417-426
14. Dingli D., Kemp B.J., O'Connor M.K., Morris JC., Russell S.J., and Lowe V.J. Combined I-124 positron emission tomography/computed tomography imaging of NIS gene expression in animal models of stably transfected and intravenously transfected tumor. Molecular Imaging and Biology 8 (2006) 16-23
15. Doll J., Henze M., Bublitz O., Werling A., Adam L.E., Haberkorn U., Semmler W., and Brix G. High resolution reconstruction of PET images using the iterative OSEM algorithm. Nuklearmedizin 43 (2004) 72-78
16. Emami B., Lyman J., Brown A., Coia L., Goitein M., Munzenrider J.E., Shank B., Solin L.J., and Wesson M. Tolerance of normal tissue to therapeutic irradiation. International Journal of Radiation Oncology, Biology, Physics 21 (1991) 109-122
17. Eschmann S.M., Reischl G., Bilger K., Kupferschlager J., Thelen M.H., Dohmen B.M., Besenfelder H., and Bares R. Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET. European Journal of Nuclear Medicine and Molecular Imaging 29 (2002) 760-767
18. Ferrari, P., Gualdrini, G., 2007. Mcnpx internal dosimetry studies based on the norman-05 Voxel model. Radiation Protection Dosimetry 127(1-4), 209-213.
19. Flux G., Bardies M., Monsieurs M., Savolainen S., Strands S.E., and Lassmann M. The impact of PET and SPECT on dosimetry for targeted radionuclide therapy. Zeitschrift fur medizinische Physik 16 (2006) 47-59
20. Furhang E.E., Sgouros G., and Chui C.S. Radionuclide photon dose kernels for internal emitter dosimetry. Medical Physics 23 (1996) 759-764
21. Gear J.I., Charles-Edwards E., Partridge M., and Flux G.D. A quality-control method for SPECT-based dosimetry in targeted radionuclide therapy. Cancer Biotherapy & Radiopharmaceuticals 22 (2007) 166-174
22. Hobbs R.F., and Sgouros G. Calculation of the biological effective dose for piecewise defined dose-rate fits. Medical Physics 36 (2009) 904-907
23. Jentzen W., Weise R., Kupferschlager J., Freudenberg L., Brandau W., Bares R., Burchert W., and Bockisch A. Iodine-124 PET dosimetry in differentiated thyroid cancer: recovery coefficient in 2D and 3D modes for PET(/CT) systems. European Journal of Nuclear Medicine and Molecular Imaging 35 (2008) 611-623
24. Kinahan P.E., Townsend D.W., Beyer T., and Sashin D. Attenuation correction for a combined 3D PET/CT scanner. Medical Physics 25 (1998) 2046-2053
25. Lazarescu G.R., and Battista J.J. Analysis of the radiobiology of ytterbium-169 and iodine-125 permanent brachytherapy implants. Physics in Medicine and Biology 42 (1997) 1727-1736
26. MATLAB, 2006. The MathWorks, Natick, MA.
27. Millar W.T. Application of the linear-quadratic model with incomplete repair to radionuclide directed therapy. British Journal of Radiology 64 (1991) 242-251
28. O'Donoghue J.A., Baidoo N., Deland D., Welt S., Divgi C.R., and Sgouros G. Hematologic toxicity in radioimmunotherapy: dose-response relationships for I-131 labeled antibody therapy. Cancer Biotherapy & Radiopharmaceuticals 17 (2002) 435-443
29. O'Donoghue J.A., and Wheldon T.E. Targeted radiotherapy using Auger electron emitters. Physics in Medicine and Biology 41 (1996) 1973-1992
30. Ott R.J. Imaging technologies for radionuclide dosimetry. Physics in Medicine and Biology 41 (1996) 1885-1894
31. Pauwels S., Barone R., Walrand S., Borson-Chazot F., Valkema R., Kvols L.K., Krenning E.P., and Jamar F. Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogs. Journal of Nuclear Medicine 46 Suppl. 1 (2005) 92S-98S
32. Pentlow K.S., Graham M.C., Lambrecht R.M., Cheung N.K., and Larson S.M. Quantitative imaging of I-124 using positron emission tomography with applications to radioimmunodiagnosis and radioimmunotherapy. Medical Physics 18 (1991) 357-366
33. Pinchuk A.N., Rampy M.A., Longino M.A., Skinner R.W., Gross M.D., Weichert J.P., and Counsell R.E. Synthesis and structure-activity relationship effects on the tumor avidity of radioiodinated phospholipid ether analogues. Journal of Medicinal Chemistry 49 (2006) 2155-2165
34. Rahmim A., and Zaidi H. PET versus SPECT: strengths, limitations and challenges. Nuclear Medicine Communications 29 (2008) 193-207
35. Rault E., Vandenberghe S., Van Holen R., De Beenhouwer J., Staelens S., and Lemahieu I. Comparison of image quality of different iodine isotopes (I-123, I-124, and I-131). Cancer Biotherapy & Radiopharmaceuticals 22 (2007) 423-430
36. Ravinder, K.G., Mark, L., Keith, S.P., Steven, M.L., 2007. The role of iodine-124-positron emission tomography imaging in the management of patients with thyroid cancer. PET Clinics 2, 313-320.
37. Roberson P.L., and Buchsbaum D.J. Reconciliation of tumor dose response to external beam radiotherapy versus radioimmunotherapy with 131iodine-labeled antibody for a colon cancer model. Cancer Research 55 (1995) 5811s-5816s
38. Sachs R.K., Hahnfeld P., and Brenner D.J. The link between low-LET dose-response relations and the underlying kinetics of damage production/repair/misrepair. International Journal of Radiation Biology 72 (1997) 351-374
39. Sgouros G., Kolbert K.S., Sheikh A., Pentlow K.S., Mun E.F., Barth A., Robbins R.J., and Larson S.M. Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software. Journal of Nuclear Medicine 45 (2004) 1366-1372
40. Stabin M.G., and da Luz L.C. Decay data for internal and external dose assessment. Health Physics 83 (2002) 471-475
41. Stabin M.G., Sparks R.B., and Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. Journal of Nuclear Medicine 46 (2005) 1023-1027
42. Strand S.E., Zanzonico P., and Johnson T.K. Pharmacokinetic modeling. Medical Physics 20 (1993) 515-527
43. Thomas S.R. Options for radionuclide therapy: from fixed activity to patient-specific treatment planning. Cancer Biotherapy & Radiopharmaceuticals 17 (2002) 71-82
44. Weichert J.P., Moser A.R., Weber S.M., Qi C., and Longino M.A. Radioiodinated NM404-a universal tumor imaging agent. Academic Radiology 12 (2005) S58-S59
45. Williams L.E., DeNardo G.L., and Meredith R.F. Targeted radionuclide therapy. Medical Physics 35 (2008) 3062-3068
46. Yang Y., and Xing L. Optimization of radiotherapy dose-time fractionation with consideration of tumor specific biology. Medical Physics 32 (2005) 3666-3677
47. Yoriyaz H., Stabin M.G., and dos Santos A. Monte Carlo MCNP-4B-based absorbed dose distribution estimates for patient-specific dosimetry. Journal of Nuclear Medicine 42 (2001) 662-669